Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07444398) titled 'Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial' on Feb. 26.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).
Primary Sponsor: Khawaja Danish Ali
Condition:
Decompensated Heart Failure
Intervention:
Drug: Vericiguat tablet
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: January 1, 2026
Target Sample Size: 130
Countries of Recruitment:
Pakistan
To know more, visit https://clinicaltrials....